Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule
Scholar Rock Holding (NASDAQ:SRRK) said the FDA review of its apitegromab BLA for spinal muscular atrophy will proceed using only its secondary fill-finish facility after an OAI tied to Catalent Indiana. The company withdrew the Catalent site from the submission. The PDUFA action date remains Sept. 30. Shares were down 3.14% to $51.26.
How this was made
The 30-second read
Why it matters
FDA will evaluate the BLA using only the secondary fill-finish facility after an OAI classification tied to a Catalent Indiana site, while the Sept. 30 PDUFA action date remains on track. EMA discussions continue for integrating the secondary site into the European application, with a revised CHMP opinion schedule to follow alignment.
Market read
Traders should focus on approval-probability and timing as the FDA manufacturing issue is contained to one site without resetting the Sept. 30 action date.
What to watch
The article does not quantify how the OAI affects specific CMC datasets or whether additional comparability/validation work is required, which could influence approval probability.
Background
Scholar Rock’s apitegromab BLA for SMA originally included two manufacturing sites to preserve independent regulatory pathways.
Ticker impact
Scholar Rock says FDA BLA review for apitegromab will proceed using only the secondary fill-finish facility after a Catalent Indiana OAI site withdrawal.
Near-term volatility likely around FDA manufacturing acceptance signals, but the unchanged Sept. 30 action date should limit downside versus a delay scenario.
The article’s key incremental fact is the OAI-driven withdrawal of one site while maintaining the PDUFA timeline, which is typically supportive for probability-weighted approval timing.
Market effects
Highlights ongoing regulatory sensitivity to fill-finish/manufacturing site readiness in biotech BLA reviews.
Limited direct regional impact; includes EMA dialogue for European marketing authorization schedule alignment.
Supports broader read-through that FDA manufacturing OAI outcomes can be mitigated via alternative qualified sites without resetting review timelines.
Counterpoint
Even with the PDUFA date unchanged, relying on a single alternative site could increase the risk of late-stage data or inspection-related issues that still emerge before the action date.
Key entities
- companyScholar Rock Holding Corporation
NASDAQ-listed biopharma developing apitegromab for spinal muscular atrophy, with an FDA BLA manufacturing-site pivot reported.
- drugapitegromab
Scholar Rock’s biologic under FDA BLA review for children and adults with SMA.
- regulatorFood and Drug Administration (FDA)
Issued an OAI classification after an April 2026 site inspection and is proceeding with review using the alternative facility.
- manufacturing_facilityCatalent Indiana LLC
Facility associated with Novo Nordisk that received an OAI classification, prompting withdrawal from the BLA submission.
- companyNovo Nordisk A/S
Associated with the Catalent Indiana facility referenced as having received the OAI classification.
